Dynavax (NASDAQ: DVAX) reported Q2 EPS of $0.08, $0.02 better than the analyst estimate of $0.06. Revenue for the quarter came in at $73.8 million versus the consensus estimate of $76.04 million.

2024 FINANCIAL GUIDANCE

Dynavax is reiterating its full year 2024 financial guidance, based on the Company\'s current operating plan:

HEPLISAV-B net product revenue between approximately $265 - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany
HEPLISAV-B gross margin of approximately 80%
Research and development expenses between approximately $60 - $75 million
Selling, general and administrative expenses between approximately $160 - $180 million
Cash, cash equivalents and marketable securities to be higher as of December 31, 2024, compared to December 31, 2023

For earnings history and earnings-related data on Dynavax (DVAX) click here.